References
- Ciccia F, Triolo G, Rizzo A. Psoriatic arthritis. N Engl J Med. 2017;376:2094–2095.
- Benson JM, Sachs CW, Treacy G. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29:615–624.
- Eder L, Thavaneswaran A, Pereira D, et al. Prevalence of monoclonal gammopathy among patients with psoriatic arthritis. J Rheumatol. 2012;39:564–567.
- Matthes T, Manfroi B, Zeller A, et al. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow. Leukemia. 2015;29:1882–1890.
- Payet J, Livartowski J, Kavian N. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013;54:767–777.
- Sidana S, Rajkumar SV, Dispenzieri A, et al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol. 2017;92:668–673.
- Brown LM, Gridley G, Check D, et al. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111:3388–3394.
- Przepiera-Będzak H, Fischer K, Brzosko M. Serum IL-6 and IL-23 levels and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome. Mediators Inflamm. 2015;2015:785705.
- Muramatsu S, Kubo R, Nishida E, et al. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod Rheumatol. 2017;27:137–141.
- Ramakrishnan V, D’Souza A. Signaling pathways and emerging therapies in multiple myeloma. Curr Hematol Malig Rep. 2016;11:156–164.
- Blimark C, Holmberg E, Mellqvist U-H, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–113.
- Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211–1225.
- Mohty M, Brissot E, Savani BN, et al. Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant. 2013;19:1416–1420.